RenovoRx (RNXT) EBT (2020 - 2026)
RenovoRx (RNXT) posted EBT of -$3.5 million for Q1 2026, up 1.14% sequentially from -$3.5 million in Q4 2025, and down 1.66% YoY from -$3.5 million in Q1 2025.
RenovoRx (RNXT) EBT (2020 - 2026) Analysis & Trends
RenovoRx has reported EBT for 7 years, with the latest figure at -$3.5 million in Q1 2026.
- Quarterly EBT fell 1.66% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.7 million (up 49.53% YoY) and the FY2025 annual result came in at -$32.3 million, down 16.42% from the prior year.
- EBT improved to -$3.5 million in Q1 2026 per RNXT's latest filing, from -$3.5 million in the prior quarter.
- Over five years, EBT peaked at -$2.7 million in Q4 2023 and troughed at -$19.4 million in Q4 2024.
- A 5-year average of -$4.5 million and a median of -$3.4 million in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2025: EBT plunged 612.51% in 2024, then jumped 81.86% in 2025.
- Over 5 years, EBT stood at -$3.1 million in 2022, then rose by 12.04% to -$2.7 million in 2023, then slumped by 612.51% to -$19.4 million in 2024, then surged by 81.86% to -$3.5 million in 2025, then grew by 1.14% to -$3.5 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$3.5 million, -$3.5 million, and -$4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | -3.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.77 Mn |
| Mar 31, 2026 | -3.48 Mn |
| Dec 31, 2025 | -3.52 Mn |
| Sep 30, 2025 | -4.06 Mn |
| Jun 30, 2025 | -3.67 Mn |
| Mar 31, 2025 | -3.43 Mn |
| Dec 31, 2024 | -19.42 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -3.32 Mn |
| Mar 31, 2024 | -3.02 Mn |
| Dec 31, 2023 | -2.73 Mn |
| Sep 30, 2023 | -3.33 Mn |
| Jun 30, 2023 | -4.23 Mn |
| Mar 31, 2023 | -5.39 Mn |
| Dec 31, 2022 | -3.10 Mn |
| Sep 30, 2022 | -2.88 Mn |
| Jun 30, 2022 | -3.33 Mn |
| Mar 31, 2022 | -4.31 Mn |
| Dec 31, 2021 | -1.62 Mn |
| Sep 30, 2021 | -5.21 Mn |